Cassava Sciences Inc

Filana Therapeutics, Inc. is a clinical-stage biotechnology company that develops drugs for neurodegenerative diseases. Its lead therapeutic candidate is simufilam, a small molecule drug that has completed a Phase 2 clinical trial. Its investigational diagnostic candidate is SavaDx, a blood-based biomarker/diagnostic intended to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. It was incorporated in 1998 and is based in Austin, Texas.